Companies › Apollo Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Cardiovascular, Immunology, Hematology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APL-9796 | – | Phase 2 | Pulmonary Arterial Hypertension | Aug 2027 |
| Camoteskimab Interleukin-18 cross-linking agent | IL18 | Phase 2 | Atopic Dermatitis | Oct 2027 |
| APL-4098 | – | Phase 1 | Acute Myeloid Leukemia Refractory | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06372717 | APL-4098 | Phase 1 | Acute Myeloid Leukemia Refractory | Hematology | Jul 2027 |
| NCT06846554 | APL-9796 | Phase 2 | Pulmonary Arterial Hypertension | Cardiovascular | Aug 2027 |
| NCT07599813 | Camoteskimab | Phase 2 | Atopic Dermatitis | Immunology | Oct 2027 |
GCP-Service International West HK inno.N Hemab ApS Viatris Innovation MRM Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.